# TCF1 ENGINEERING: PARTNERSHIP INFOGRAPHIC

**Document Type:** Visual Pitch Deck  
**Format:** 6-slide deck  
**Audience:** TCF1 Researchers (Autoimmunity + Cancer Immunotherapy)  
**Purpose:** Email-ready partnership proposal

---

## **DESIGN PRINCIPLES**

**Tone:** Collaborative, hypothesis-driven, dual-disease opportunity  
**Visual Hierarchy:** Discovery â†’ Paradox â†’ Solutions â†’ Pilot â†’ Value  
**Color Palette:**  
- Red (#C8102E) for autoimmunity findings  
- Blue (#0052CC) for cancer immunity findings  
- Purple gradient where they intersect (TCF1 is the common link)

**Key Message:** "TCF1 is a brake in autoimmunity, but an enabler in cancer. We engineer solutions for both."

---

## **SLIDE 1: THE DISCOVERY â€“ TCF1'S DUAL ROLE**

### **Header:**
**"TCF1: The Master Switch Between Homeostasis and Inflammation, Survival and Death"**

### **Visual:**
```
[LEFT HALF - AUTOIMMUNITY (RED)]
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Th17 Cells (CD4)               â”‚
â”‚                                â”‚
â”‚ HIGH TCF1 = GOOD               â”‚
â”‚ âœ… Homeostatic                 â”‚
â”‚ âœ… IL-10 production            â”‚
â”‚ âœ… Binds RORÎ³t (inhibits)      â”‚
â”‚                                â”‚
â”‚ LOW TCF1 = BAD                 â”‚
â”‚ âŒ Inflammatory                â”‚
â”‚ âŒ IL-17 production            â”‚
â”‚ âŒ Drives MS/Diabetes/Psoriasisâ”‚
â”‚                                â”‚
â”‚ TRIGGER: IL-23 suppresses TCF1 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

[RIGHT HALF - CANCER IMMUNITY (BLUE)]
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ CD8 T-Cells (Tumor-Infiltrating)â”‚
â”‚                                â”‚
â”‚ HIGH TCF1 = GOOD               â”‚
â”‚ âœ… Stemness maintenance        â”‚
â”‚ âœ… Tox induction (survival)    â”‚
â”‚ âœ… Checkpoint response         â”‚
â”‚                                â”‚
â”‚ LOW TCF1 = BAD                 â”‚
â”‚ âŒ Dysfunctional cells die     â”‚
â”‚ âŒ Low Tox expression          â”‚
â”‚ âŒ Immunotherapy fails         â”‚
â”‚                                â”‚
â”‚ CONTEXT: Critical in low-      â”‚
â”‚ antigen tumors (B16)           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

[CENTER - PURPLE OVERLAP]
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ TCF7 SNPs Linked To:           â”‚
â”‚ â€¢ MS, T1D, RA, Psoriasis       â”‚
â”‚ â€¢ Checkpoint toxicity (?)      â”‚
â”‚                                â”‚
â”‚ MECHANISM: UNKNOWN             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### **Footer:**
> **"Your work proves TCF1 is the pivot. High = homeostasis + tumor survival. Low = autoimmunity + immunotherapy failure. The paradox: same molecule, opposite diseases."**

---

## **SLIDE 2: THE PARADOX â€“ ONE MOLECULE, TWO PROBLEMS**

### **Header:**
**"The $100B Question: How Do We Stabilize TCF1 in Cancer Without Worsening Autoimmunity?"**

### **Visual:**
```
[DISEASE BURDEN DIAGRAM]

AUTOIMMUNITY (TCF1-LOW)            CANCER (TCF1-LOW)
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€               â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
â€¢ 23M Americans with               â€¢ 70% checkpoint failure
  autoimmune diseases                (TCF1-low Tex die)
â€¢ $100B/year treatment             
â€¢ SNPs in TCF7 = risk              â€¢ B16-like tumors
                                     (low antigen) most
â†“ TCF1                               vulnerable
(IL-23 suppression)                
                                   â†“ TCF1
MS, T1D, RA, Psoriasis             (context-dependent)
                                   
                                   Poor Tox induction
                                   â†’ Apoptosis

[CENTER - THE CHALLENGE]
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Can we engineer TISSUE-SPECIFIC or               â”‚
â”‚ CONTEXT-DEPENDENT TCF1 modulation?               â”‚
â”‚                                                  â”‚
â”‚ â€¢ BOOST TCF1 in tumors â†’ better Tex survival    â”‚
â”‚ â€¢ BOOST TCF1 in Th17 â†’ prevent autoimmunity     â”‚
â”‚ â€¢ PROFILE TCF7 SNPs â†’ predict risk              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### **Footer:**
> **"Current therapies are one-size-fits-all. We need precision tools: stabilize TCF1 where it's protective, understand SNPs that alter risk, engineer T-cells with optimized TCF1 circuits."**

---

## **SLIDE 3: OUR SOLUTION â€“ 4 ENGINEERING TOOLS**

### **Header:**
**"From Descriptive Biology to Precision Engineering"**

### **Visual:**
```
[FOUR TOOLS - TABLE FORMAT]

TOOL #1: TCF1/Tox Signature           TOOL #2: TCF1 Stabilization
(DIAGNOSTIC)                          (AUTOIMMUNITY)
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€             â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
â€¢ RNA-seq â†’ TCF1/RORÎ³t/Tox/           â€¢ Design A: Anti-IL-23R decoy
  IL-23R levels                         (block TCF1 suppression)
                                      
â€¢ Predicts:                           â€¢ Design B: TCF1 overexpression
  - Autoimmune risk                     cassette (AAV delivery)
  - Checkpoint response               
  - Checkpoint toxicity (?)           â€¢ Outcome: Maintain homeostatic
                                        Th17, prevent disease
Confidence: âš ï¸ MEDIUM                  
(needs validation cohort)             Confidence: âœ… HIGH
                                      (design tools validated)

TOOL #3: TCF1-Enhanced CAR-T          TOOL #4: SNP Functional
(CANCER)                              Profiling (PRECISION)
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€             â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
â€¢ CAR + sustained TCF1                â€¢ Take TCF7 SNP patient
  expression                          
                                      â€¢ Measure TCF1/RORÎ³t/Tox
â€¢ Mechanism:                            signature
  - Better Tox induction              
  - Better survival in TME            â€¢ Classify SNP:
  - Better checkpoint response          - Loss-of-function
                                        - Binding-defective
â€¢ Target: B16-like (low antigen)       - Gain-of-function
  tumors                              
                                      â€¢ Predict: Disease risk,
Confidence: âš ï¸ MEDIUM                   treatment response
(hypothesis, needs validation)        
                                      Confidence: ðŸ”´ LOW
                                      (needs SNP cohort)
```

### **Footer:**
> **"We don't just describe TCF1's roleâ€”we engineer solutions. Diagnostics to predict risk. Interventions to stabilize TCF1. Precision tools to profile SNPs."**

---

## **SLIDE 4: THE 8-WEEK PILOT â€“ WHAT WE'LL TEST**

### **Header:**
**"$0 Cost. Two Disease Models. 8 Weeks. Co-Author If It Works."**

### **Visual:**
```
[TIMELINE]

WEEK 1-2: Data Transfer
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Partner Provides:               â”‚
â”‚                                 â”‚
â”‚ AUTOIMMUNITY ARM:               â”‚
â”‚ â€¢ 20 Th17 samples (Homeostatic  â”‚
â”‚   vs Inflammatory)              â”‚
â”‚ â€¢ RNA-seq                       â”‚
â”‚ â€¢ Clinical data (MS/T1D onset?) â”‚
â”‚                                 â”‚
â”‚ CANCER ARM:                     â”‚
â”‚ â€¢ 20 TIL samples (Responders vs â”‚
â”‚   Non-responders to checkpoint) â”‚
â”‚ â€¢ RNA-seq (baseline + on-tx)    â”‚
â”‚ â€¢ TCF1/Tox IHC (if available)   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

WEEK 3-4: Signature Building (HYPOTHESIS TEST)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ AUTOIMMUNITY:                   â”‚
â”‚ â€¢ Correlate TCF1/RORÎ³t/IL-23R   â”‚
â”‚   with inflammatory phenotype   â”‚
â”‚ â€¢ Hypothesis: Low TCF1 predicts â”‚
â”‚   disease onset (r > 0.60)      â”‚
â”‚                                 â”‚
â”‚ CANCER:                         â”‚
â”‚ â€¢ Correlate TCF1/Tox with       â”‚
â”‚   checkpoint response           â”‚
â”‚ â€¢ Hypothesis: High TCF1 + Tox   â”‚
â”‚   predicts response (r > 0.60)  â”‚
â”‚                                 â”‚
â”‚ âœ… Success: r > 0.60 â†’ HIGH confâ”‚
â”‚ ðŸ”„ Pivot: r < 0.50 â†’ refine     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

WEEK 5-6: Intervention Design
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â€¢ Design 3 interventions:       â”‚
â”‚   1. IL-23 decoy (autoimmunity) â”‚
â”‚   2. TCF1 overexpression (both) â”‚
â”‚   3. TCF1-CAR-T (cancer)        â”‚
â”‚                                 â”‚
â”‚ â€¢ Off-target analysis           â”‚
â”‚ â€¢ Immunogenicity prediction     â”‚
â”‚ â€¢ Manufacturing feasibility     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

WEEK 7-8: Deliverables Package
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ 1. TCF1/Tox signature (both     â”‚
â”‚    diseases)                    â”‚
â”‚ 2. 3 intervention designs with  â”‚
â”‚    validation protocols         â”‚
â”‚ 3. SNP profiling tool (if SNP   â”‚
â”‚    data available)              â”‚
â”‚ 4. Calibration report (r-values)â”‚
â”‚ 5. Go/No-Go recommendation      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### **Footer:**
**IF ASSUMPTIONS FAIL - PIVOT PLAN:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â€¢ RNA r < 0.50 â†’ Single-cell RNA-seq for higher   â”‚
â”‚   resolution; identify cell subsets              â”‚
â”‚ â€¢ SNPs unavailable â†’ Build signature without SNP  â”‚
â”‚   stratification; recommend follow-up cohort     â”‚
â”‚ â€¢ Designs fail validation â†’ ID which contexts     â”‚
â”‚   TCF1 modulation works vs. doesn't              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Cost: $0. Exit anytime. You keep all designs/code if it fails.**

---

## **SLIDE 5: THE VALUE PROPOSITION**

### **Header:**
**"What You Get: Diagnostics + Therapeutics + Publications"**

### **Visual:**
```
[THREE VALUE PILLARS]

PILLAR 1: DIAGNOSTIC TOOLS          PILLAR 2: THERAPEUTIC DESIGNS
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ â€¢ TCF1/Tox signature     â”‚       â”‚ â€¢ IL-23 decoy receptor   â”‚
â”‚   (predicts autoimmune   â”‚       â”‚   (block TCF1 suppress.) â”‚
â”‚   risk + checkpoint      â”‚       â”‚                          â”‚
â”‚   response)              â”‚       â”‚ â€¢ TCF1 overexpression    â”‚
â”‚                          â”‚       â”‚   cassette (AAV)         â”‚
â”‚ â€¢ SNP profiling tool     â”‚       â”‚                          â”‚
â”‚   (functional prediction)â”‚       â”‚ â€¢ TCF1-enhanced CAR-T    â”‚
â”‚                          â”‚       â”‚   (better persistence)   â”‚
â”‚ â€¢ Patient stratification â”‚       â”‚                          â”‚
â”‚   for trials             â”‚       â”‚ â€¢ Manufacturing protocolsâ”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

PILLAR 3: PUBLICATIONS & IP
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ AUTOIMMUNITY:                                  â”‚
â”‚ â€¢ TCF1 signature validation (Immunity, JCI)    â”‚
â”‚ â€¢ IL-23/TCF1 axis intervention (Nat Med)       â”‚
â”‚                                                â”‚
â”‚ CANCER:                                        â”‚
â”‚ â€¢ TCF1/Tox predictive biomarker (JCO, Cancer   â”‚
â”‚   Cell)                                        â”‚
â”‚ â€¢ TCF1-CAR-T validation (Nat Med, Blood)       â”‚
â”‚                                                â”‚
â”‚ IP TERMS: 70/30 split (Partner 70%, CrisPRO 30%)â”‚
â”‚ Co-authorship on all publications              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### **Footer:**
> **"This partnership creates tools NO competitor can replicate. Your TCF1 biology expertise + our engineering platform = diagnostic biomarkers, precision therapeutics, and dual-disease publications."**

---

## **SLIDE 6: WHY THIS PARTNERSHIP? WHY NOW?**

### **Header:**
**"Strategic Timing: Capture The TCF1 Opportunity Before Others"**

### **Visual:**
```
[THREE URGENCY PILLARS]

âœ… YOUR DISCOVERY IS FOUNDATIONAL      â° DUAL-DISEASE OPPORTUNITY
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€         â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
TCF1's dual role (autoimmunity +       $100B autoimmunity market
cancer) is YOUR finding                
                                       $50B checkpoint market
First-mover advantage for              
building signatures/interventions      Solving one disease unlocks
                                       the other (same molecule)
Capture data moat NOW before           
others build competing tools           


â° SNP MYSTERY AWAITS SOLUTION         ðŸŽ¯ PARTNERSHIP FLYWHEEL
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€           â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
TCF7 SNPs linked to 4+ diseases        Your biology â†’ trains our
but mechanism UNKNOWN                  models
                                       
Profile 100+ SNP patients â†’            Our designs â†’ your validation
unlock precision medicine              
                                       Your outcomes â†’ improve our
$10B+ market for SNP-based             tools
stratification tools                   
                                       Learning loop = compound
                                       advantage
```

### **Footer:**
> **"The opportunity window is NOW. Your TCF1 discoveries are foundational. Your data trains proprietary algorithms. This partnership positions you as the TCF1 engineering leaderâ€”bridging autoimmunity and cancer immunity in one platform."**

---

## **EMAIL-READY SUMMARY (PASTE INTO MESSAGE)**

**Subject:** Partnership Proposal: TCF1 Engineering (Autoimmunity + Cancer Immunity)

**Body:**

Dr. [Name],

Your work on TCF1 is foundationalâ€”proving it's a brake in autoimmunity (binds RORÎ³t, prevents inflammatory Th17) and an enabler in cancer immunity (induces Tox, enables dysfunctional T-cell survival).

**The Gap:** We know WHAT TCF1 does. But we can't PREDICT who's at risk (SNPs? RNA signature?) or ENGINEER precision solutions (tissue-specific TCF1 modulation).

**Our Proposal:** 8-week pilot, $0 cost, dual-disease approach

**AUTOIMMUNITY ARM:**
- 20 Th17 samples (homeostatic vs inflammatory) with RNA-seq
- Build TCF1/RORÎ³t/IL-23R signature â†’ predict disease onset
- Design 2 interventions: IL-23 decoy, TCF1 overexpression

**CANCER ARM:**
- 20 TIL samples (checkpoint responders vs non-responders) with RNA-seq
- Build TCF1/Tox signature â†’ predict response
- Design TCF1-enhanced CAR-T (better persistence in hostile TME)

**Deliverables:**
1. TCF1/Tox signature for both diseases (predictive biomarker)
2. 3 intervention designs with validation protocols
3. SNP profiling tool (if SNP data available)
4. Calibration report (r-values, performance metrics)

**Hypothesis:** RNA-seq predicts phenotype (target: r > 0.60; lit baseline: variable)  
**Pivot Plan:** If r < 0.50, recommend single-cell RNA-seq or spatial profiling

**Cost:** $0. Co-author + co-own IP if it works. You keep everything if it fails.

**Value:** One signature, two diseases, dual publications (Immunity + JCO). De-risk 3 years of experiments.

Attached: 6-slide visual deck outlining pilot, deliverables, and partnership terms.

Can we schedule 60 minutes to discuss?

Best,  
[Your Name]  
CrisPRO.ai

---

## **PRESENTATION SCRIPT (2-MINUTE VERSION)**

**SLIDE 1:**
> "Your work proves TCF1 is the master switch. High TCF1 maintains homeostatic Th17 cells and enables dysfunctional T-cell survival in tumors. Low TCF1 drives autoimmunity and immunotherapy failure. It's a brake in one disease, an enabler in the otherâ€”the same molecule, opposite problems."

**SLIDE 2:**
> "The paradox creates a $150B opportunity. 23 million Americans have autoimmune diseases driven by TCF1-low inflammatory Th17. 70% of checkpoint patients fail because TCF1-low Tex cells can't survive. TCF7 SNPs are linked to bothâ€”but we don't know which are functional. We need precision tools, not one-size-fits-all therapies."

**SLIDE 3:**
> "CrisPRO offers 4 engineering tools. First, a TCF1/Tox signatureâ€”RNA-seq predicts autoimmune risk AND checkpoint response. Second, TCF1 stabilization designsâ€”IL-23 decoys and overexpression cassettes to maintain homeostatic Th17. Third, TCF1-enhanced CAR-T for better tumor survival. Fourth, SNP functional profiling to predict disease risk and treatment response."

**SLIDE 4:**
> "The pilot is 8 weeks, $0 cost, dual-disease. You provide 20 Th17 samples and 20 TIL samples with RNA-seq. Week 1-2: data transfer. Week 3-4: build signatures, test if TCF1/Tox predicts phenotype (target r > 0.60). Week 5-6: design 3 interventions. Week 7-8: deliver signatures, designs, SNP tool, calibration report. If RNA doesn't predict (r < 0.50), we pivot to single-cell or spatialâ€”you keep all code and designs."

**SLIDE 5:**
> "What you get: Diagnostic biomarkers for patient stratification. Three precision therapeutics with manufacturing protocols. Co-authorship on dual-disease publicationsâ€”Immunity for autoimmunity, JCO for cancer. Joint IP with 70/30 split. And a learning systemâ€”your validation data improves our models, compounding your advantage."

**SLIDE 6:**
> "Why now? Your TCF1 discoveries are foundationalâ€”this is your window to capture the data moat before others build competing tools. It's a dual-disease opportunityâ€”$150B combined market, same molecule. TCF7 SNPs are a mystery awaiting solutionâ€”profile 100 patients, unlock precision medicine. This partnership positions you as the TCF1 engineering leader, bridging two fields that have never been connected."

---

**INFOGRAPHIC STATUS:** ðŸŸ¢ **EMAIL-READY**  
**Format:** 6 slides, 2-min script, email summary included  
**Tone:** Collaborative, hypothesis-driven, dual-disease opportunity  
**Key Differentiator:** Only platform bridging autoimmunity + cancer with TCF1 engineering
